WHAT IS CLAIMED IS:

1. Use of lesinurad in combination with allopurinol in the manufacture of a medicament for treating gout in a patient on concomitant thiazide diuretics.
2. The use of claim 1, wherein a dose of lesinurad is 200 mg.
3. The use of claim 1, wherein a dose of lesinurad is 400 mg.
4. Use of an OAT4 inhibitor in combination with allopurinol in the manufacture of a medicament for reducing the incidences of or likelihood of or reversing hyperuricemia or gout in a patient receiving thiazide treatment, wherein the OAT4 inhibitor is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof.

~~5. The use of claim 4, wherein the OAT4 inhibitor is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof.~~

6.5. The use of claim 4, wherein the thiazide treatment is treatment with hydrochlorothiazide, bendroflumethiazide, benzthiazide~~benzothiadiazine~~, hydroflumethiazide, chlorothiazide, methyclothiazide, polythiazide, chlorthalidone, metolazone, indapamide, quinethazone, or trichlormethiazide ~~bumetanide, ethacrynic acid, furosemide or torsemide~~.

7.6. Use of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof in combination with allopurinol in the manufacture of a medicament for reducing or reversing hyperuricemia or gout in a patient receiving hydrochlorothiazide.

8.7. Use of an OAT4 inhibitor in combination with allopurinol in the manufacture of a medicament for reducing serum uric acid levels in a patient suffering from hypertension, wherein the patient is receiving a thiazide diuretic, and wherein administration of the thiazide diuretic results in elevated serum uric acid levels, wherein OAT4 inhibitor is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof.

~~9. The use of claim 8, wherein the OAT4 inhibitor is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof.~~

10.8. A composition comprising:

i. a thiazide diuretic;
ii. an OAT4 inhibitor, wherein the OAT4 inhibitor is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof;
iii. allopurinol; and
iv. a pharmaceutically acceptable excipient or carrier.

11.9. A composition comprising:

i. a thiazide diuretic;

ii. 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof;

iii. allopurinol; and

iv. a pharmaceutically acceptable excipient or carrier.

~~12.~~10. A composition comprising:

i. hydrochlorothiazide;

ii. 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof;

iii. allopurinol; and

iv. a pharmaceutically acceptable excipient or carrier.